Board of Directors
Elizabeth Holmes, Founder, CEO
Elizabeth A. Holmes is President and Chief Executive Officer of Theranos, Inc. Holmes’ unique background in microfluidics and nanotechnology led her to found Theranos around her patent, Medical Device for Analyte Monitoring and Drug Release, and the vision to create a new sector of personalized health care enabling individuals to take control of their health through real-time diagnosis, monitoring, and treatment of targeted ailments in a non-invasive fashion. She took the company from concept to reality, building a world-class management team and leading the product and commercial development infrastructures from inception through to manufacturing for pharmaceutical partners today. Holmes left Stanford University to found Theranos after contributing to the development of several novel biosensor systems through her work at Genome Institute Singapore and in collaboration with Genencor International.
Selected Media
Donald L. Lucas, Chairman of the Board
Mr. Lucas is well-known as a founding partner of such companies as National Semiconductor Corporation, Macromedia, Inc., PDF Solutions, Inc., and Oracle Corporation. Mr. Lucas is currently on the board of Cadence Design Systems, Inc., Chairman of the Executive Committee of the Board of Directors of Oracle Corporation (Don served as Chairman from October 1980 to May 1990), Chairman of the Board of 51Job, and Chairman of the Board of Dexcom, Inc.. In addition, Mr. Lucas serves as a Director for several other public and private companies. Mr. Lucas was a General and Limited Partner of Draper, Gaither & Anderson (DG&A), the first venture capital firm, before investing independently. Don Lucas received his Bachelor of Arts degree from Stanford University and his MBA from Stanford's Graduate School of Business.
Robert B. Shapiro
Mr. Shapiro has been a director of NYSE Group since December 1, 2005. Mr. Shapiro served as a director of the NYSE from November 2003 to March 7, 2006, the date on which the merger of the NYSE and Archipelago was completed. Mr. Shapiro is former Chairman and Chief Executive Officer of Monsanto Company, a position to which he was appointed in 1995 after sixteen years with the company and its predecessor, G.D. Searle & Co., Inc. Upon the merger of Monsanto with Pharmacia & Upjohn, he served as chairman of the newly formed Pharmacia Corporation until his retirement in February 2001. Mr. Shapiro currently serves as Chairman and Managing Director of Sandbox Industries, LLC.
Peter Thomas
Peter Thomas is a co-founder and Managing Director of ATA Ventures. Pete comes to ATA Ventures having enjoyed a highly successful career in venture capital activities across the past 20 years. In 1985, he joined Institutional Venture Partners (IVP) as a General Partner in their IVP III fund and continued as a General Partner of IVP through the IVP III-VIII funds. Companies that Pete has successfully led investments in include Nellcor, Applied Medical, Atmel (ATML), Altera (ALTR), @Road (ARDI), Transmeta (TMTA), Cirrus Logic (CRUS), Form Factor (FORM), and many others. Pete is on the board of two public companies, Transmeta (TMTA) and Atmel (ATML) as well as several other private companies. Prior to venture capital activities, Pete was at Intel Corporation for 7 years in various engineering and marketing management roles. Pete graduated magna cum laude in 1968 with a BSEE degree from Utah State University and received his MS in Computer Science from the University of Santa Clara in 1975.
Channing Robertson
Channing Robertson holds the Ruth G. and William K. Bowes Professor in the School of Engineering, Stanford University, and serves as the Senior Associate Dean of Engineering at Stanford. Dr. Robertson has spent much of his career designing and developing advanced drug delivery systems for therapeutic applications. He was recently featured in Upside Magazine's special issue on "100 People Who Have Changed the World." Channing served as an expert witness in several trials including the Copper-7 intrauterine contraceptive cases (in the U.S. and Australia), the Stringfellow Superfund case and most recently the Minnesota tobacco trial where he provided testimony on tobacco material processing, cigarette design and manufacturing and nicotine delivery systems He was a Founding Fellow, American Institute of Medical and Biological Engineering, a Member of the Science, Law and Technology Law Program Committee of the National Academy of Sciences, and the Panel on Court Appointed Scientific Experts (CASE) of the American Association for the Advancement of Science. He received his BS (with Honors) in Chemical Engineering from the University of California at Berkeley and received his MS & PhD, Chemical Engineering emphasis on fluid mechanics and transport phenomena from Stanford University.
George T. Shaheen
George T. Shaheen was recently the CEO of Siebel Systems until its acquisition by Oracle Corporation. He was the Chief Executive Officer and Global Managing Partner of Andersen Consulting, which later became Accenture, from 1989-1999. He then became the CEO and Chairman of the Board of Webvan Group, Inc. Mr. Shaheen serves on the boards of Network Appliance, 24/7 Customer, newScale and he is a member of the Advisory Boards of the Marcus & Millichap Company and Genstar Capital. He has served as an IT Governor of the World Economic Forum and he is a member of the Board of Advisors for the Northwestern University Kellogg Graduate School of Management. He has also served on the Board of Trustees of Bradley University. Mr. Shaheen is a graduate of Bradley University (BS 1966 & MBA 1968).